Inactief instrument

Andere talen Hemispherx BioPharma, Inc Nyse

Aandelen

US42366C3016

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed	29/04
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer	29/04
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	25/04
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	18/04
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs	15/04
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	11/04
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	10/04
AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	10/04
Challenges To Advance Notice Bylaws Are Spiking	08/04
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	02/04
North American Morning Briefing : Stocks Seen -2-	02/04
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference	28/03
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast	26/03
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research	26/03
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	25/03
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research	25/03
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	22/03
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	20/03
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	20/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Hemispherx BioPharma, Inc Nyse

Aandelen

US42366C3016

Andere talen

Filters